Gunderson Dettmer advised client Theseus Pharmaceuticals, a biopharmaceutical company focused on improving the lives of cancer patients, on its initial public offering. The company is developing next-generation therapies that address all major drug resistance mutations.

The company announced the shares began trading on the Nasdaq Global Select Market on October 7, 2021, under the ticker symbol "THRX." Jefferies, SVB Leerink, and Cantor acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager.

The Gunderson deal team worked across offices, including corporate partner Marcia Hatch together with associates Alex Whatley and Vince Dutkowski, IPO partner Colin Conklin, together with associates Fred Martin, Frank Strumolo, and Elizabeth Gimzewski, strategic partnering & commercial transactions partner Marna Pattaropong together with associate Joel Diamond, executive compensation partner Sharon Hendricks, together with of counsel Craig Olshan and associate Erik Ward, tax partner Jaime Narayan, and corporate paralegals Scott Paraker and Mary Sullivan. 

Companies:
Theseus Pharmaceuticals